Verified product status
Tirzepatide: Approved Finished Medicines vs Research Material
FDA labeling identifies tirzepatide as the active ingredient in approved finished medicines including Zepbound. Approval applies to the named drug products, presentations, manufacturing controls and labeled conditions—not to every material sold under the ingredient name.
Dated verification
What the reviewed sources establish
A regulatory proposal, advisory recommendation, clinical-development stage and marketing approval are kept as separate findings.
FDA-approved finished tirzepatide drug products exist
Current FDA prescribing information
Ingredient-name overlap does not transfer approval to research material
Entity and formulation boundary
FDA proposed excluding tirzepatide from the 503B bulks list based on no identified clinical need
FDA April 30, 2026 announcement
Status timeline
Keep the date attached to the claim.
Later events do not retroactively change what an earlier source established. This timeline records the source context used for the current wording.
Initial U.S. approval date listed in current Zepbound labeling.
FDA label revision includes current presentations and labeled indications.
FDA announced a proposal to exclude tirzepatide from the 503B bulks list; a proposal is not rewritten here as a final rule.
Entity boundary
The name is not the approval.
A catalog tirzepatide research material must not be described as Zepbound or Mounjaro, as FDA approved, or as clinically interchangeable. Product-specific identity and lot records remain separate from the regulatory evidence for approved medicines.
Research and regulatory information only. No clinical-use or dosing guidance.Primary and technical sources
Records used for this guide
Sources are linked directly so the wording, date and scope can be checked independently.
- 01Source record
Zepbound (tirzepatide) Prescribing Information
U.S. FDA. NDA 217806; label revised January 2026.
- 02Source record
FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List
U.S. FDA press announcement, April 30, 2026.
Knowledge center